Moderna details 2023 strategic priorities; RSV trial nearly enrolled, flu vaccine accelerated pathway

Moderna, Inc.

RSV vaccine Phase 3 enrolled >36,000 of 37,000 target; flu vaccine efficacy trial initiated in Northern Hemisphere.
Personalized cancer vaccine (mRNA-4157/V940) + KEYTRUDA cut recurrence or death risk by 44% in Phase 2 melanoma study.
First inhaled mRNA candidate (Vxc-522 for cystic fibrosis) cleared by FDA; relaxin Phase 1B dosed for heart failure.
Rare disease programs show promise: propionic acidemia MDE reductions; sixth candidate (OTC deficiency) added.
2023 priorities include building respiratory franchise, aggressive cancer vaccine program, and potential flu vaccine approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.